Sequus Pharmaceuticals is engaged in the development, manufacture, marketing and sale of proprietary pharmaceutical products for the critical care market. The company is developing DOXIL to treat advanced forms of cancer, including AIDS-related Kaposi's sarcoma. In addition the company is focusing on the clinical development and commercialization of its proprietary antifungal product AMPHOCIL™. AMPHOCIL is approved in the United Kingdom , Finland and the Republic of Ireland . Sequus Pharmaceuticals went public on the NASDAQ Stock Market's and was thereafter acquired by Alza. |
